Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C
| Autor: | Jason A. Dominitz, Michael K. Chapko, Helen S. Yee, Alexander Monto |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Pediatrics
medicine.medical_specialty Cost effectiveness Cost-Benefit Analysis Hepatitis C virus Hepatitis A Infection medicine.disease_cause medicine Humans Veterans Affairs health care economics and organizations Hepatitis A Vaccines General Veterinary General Immunology and Microbiology Immunization Programs business.industry Incidence Incidence (epidemiology) Public Health Environmental and Occupational Health Hepatitis A Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Markov Chains Vaccination Infectious Diseases Immunology Molecular Medicine Quality-Adjusted Life Years business |
| Zdroj: | Vaccine. 28:1726-1731 |
| ISSN: | 0264-410X |
| Popis: | The incidence of hepatitis A infection in the United States has decreased dramatically in recent years because of childhood immunization programs. A decision analysis of the cost-effectiveness of hepatitis A vaccination for adults with hepatitis C was conducted. No vaccination strategy is cost-effective for adults with hepatitis C using the recent lower anticipated hepatitis A incidence, private sector costs, and a cost-effectiveness criterion of $100,000/QALY. Vaccination is cost-effective only for individuals who have cleared the hepatitis C virus when Department of Veterans Affairs costs are used. The recommendation to vaccinate adults with hepatitis C against hepatitis A should be reconsidered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect